- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03981913
Cognitive Control in Parkinson's Disease (EEGControl)
Study of the Neuronal Substrates of the Cognitive Action Control in Parkinson's Disease Using High Density EEG
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alterations in cognitive action control in patients with PD are well described from a behavioral point of view. However, there is currently very little information to directly link these difficulties to functional alterations of brain areas, or of efficient communication within large scale brain networks. Thus, the objective of this project is to specify the neuronal substrates linked to the difficulties in cognitive action control observed in patients with PD. The rational is based on the recent findings on the role of theta (4-8 Hz) neuronal oscillations in cognitive action control. Indeed, converging evidence linked this process to an increase in theta oscillatory power around midfrontal electrodes (FCz, Cz) and to an increase in theta functional connectivity with task-relevant brain areas.
The working hypotheses are based on the hypothesis proposed by Cohen (2014). It proposes that the medial frontal cortex (MFC; around the pre-SMA) would be involved in the integration of conflicting information, observable by studying theta oscillations' power. On the other hand, the phase synchronization of theta oscillations between the MFC and the other task-relevant cortical areas would reflect the degree of recruitment of the entire network participating in the implementation of an efficient cognitive control. Thus, according to this model, a conflict situation would lead to two main measurable electrophysiological reactions in the cortex: i) an increase in the power of theta oscillations around the MFC, ii) an increase in theta phase synchronization between the MFC and the other cortical areas (such as the lateral prefrontal and parietal cortices) involved in implementing cognitive action control. These two electrophysiological effects will be the main judgment criteria of this study.
The hypothesis is that the behavioral difficulties in cognitive action control observed in PD patients stem from a lack of integration of the conflicting information and / or a weaker communication of this information to the areas implementing the cognitive control of the action. The alteration of one or both of these aspects may explain the weaker cognitive action control observed in patients. Moreover, by inspecting the disrupted brain networks, it will be able to make hypotheses explaining the alteration of cognitive control in PD. For example, a weaker functional connectivity between the MFC and the posterior parietal cortex could indicate a lower redirection of attentional resources following the presentation of a conflictual stimulus. Another possibility would be a weaker functional connectivity between the MFC and the inferior prefrontal cortex, which would rather indicate a lack of recruitment of the inhibitory system.
The main hypothesis will be tested by comparing the performance of a group of PD patients to that of a group of healthy participants whose brain activity will be collected during the realization of a Simon task via a high resolution electroencephalography system. The behavioral performances will be compared as well as the source-reconstructed electrophysiological data. Specifically, the power of the theta oscillations within the medial frontal cortex, as well as the phase synchronization between the other cortical areas involved will be compared between the two groups. Brain-behavior relationships will also be investigated in order to try to link PD behavioral impairments to changes in theta oscillatory power/connectivity.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: cecile ferragu
- Phone Number: 02 99 28 25 55
- Email: cecile.ferragu@chu-rennes.fr
Study Contact Backup
- Name: Direction de la recherche DRI
- Phone Number: 02 99 55 25 55
- Email: drc@chu-rennes.fr
Study Locations
-
-
-
Rennes, France, 35000
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
PD patients will be recruited from the Neurology unit of the Rennes University Hospital. The study will be proposed to them during their hospitalization, which is independent from this study and occurs as part of their routine care. Most patients are hospitalized in order to conduct pre-surgical evaluations before deep brain stimulation. No changes in treatments or any other type of routine care will be made during this study.
HC volunteers will be recruited from the general population using a volunteer database from our lab. HC's travel expenses will be refunded by the hospital
Description
Inclusion Criteria:
Applicable to all participants (HC and PD patients):
- Age over 18
- Correct or corrected-to-normal vision
- Affiliation to a social security scheme
- Subject having received the information on the protocol and having not manifested his/her opposition to participate.
Exclusive to patients:
- Idiopathic Parkinson's disease according to the criteria of the United Kingdom Parkinson's Disease Brain Bank Society
Exclusion Criteria:
Applicable to all participants (HC and PD patients):
- Inability to understand the information given about the study or to perform the experimental task;
- Major cognitive impairment (Moca<22) or severe neurocognitive disorder according to the DSM-V (Diagnostic and statistical manual of mental disorders -V);
- Motor difficulties preventing the performance of the task
- Addiction to drugs or alcohol;
- Major person subject to legal protection (safeguard of justice, guardianship), persons deprived of their liberty.
- Present or past moderate to severe psychiatric pathology (obsessive-compulsive disorder, bipolar disorder, schizophrenia, etc.);
Exclusive to patients:
- Present or past neurological pathology other than Parkinson's disease (cerebrovascular accident, head trauma, etc.);
- Treatment by deep brain stimulation.
Exclusive to healthy participants:
- Present or past neurological pathology
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy control (HC)
Participants without neurological or psychiatric disturbance (n= 30)
|
The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc). During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected. |
Parkinson's disease (PD)
Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
|
The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc). During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in theta source connectivity between PD patients and matched HC in the medial-frontal-prefrontal-parietal regions following conflict situations
Time Frame: 45 minutes
|
The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc.) placed in the 10-20 and 10-5 systems with a 1000 Hertz sampling rate.
The 256 electrodes are arranged on a cap, the electrode placement takes only 5 minutes.
Before applying the cap, we will have measured the cranial perimeter of the participant to choose the most suitable cap, three sizes of caps being available.
A baseline period will be obtained by recording a 10 minutes resting state activity.
|
45 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in MFC theta source power between PD patients and matched HC following conflict situations
Time Frame: 45 minutes
|
The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc.) placed in the 10-20 and 10-5 systems with a 1000 Hertz sampling rate.
The 256 electrodes are arranged on a cap, the electrode placement takes only 5 minutes.
Before applying the cap, we will have measured the cranial perimeter of the participant to choose the most suitable cap, three sizes of caps being available.
A baseline period will be obtained by recording a 10 minutes resting state activity.
|
45 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jean-François Houvenaghel, Rennes University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35RC19_8963_EEGControl
- 2019-A00608-49 (Other Identifier: ANSM ( french national agency for drugs))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on Simon Task with high-density EEG recording
-
IRCCS Eugenio MedeaRecruitingEpilepsy | Angelman Syndrome | Dup15q SyndromeItaly
-
Hôpital le VinatierNot yet recruitingEmotion Recognition | Child Sexual AbuseFrance
-
Karl Landsteiner Institute for Clinical Epilepsy...AIT Austrian Institute of Technology GmbH; Brainhero GmbHRecruiting
-
University Hospital, LilleRecruitingIdiopathic Generalized EpilepsyFrance
-
University Hospital, Strasbourg, FranceRecruiting
-
Dartmouth-Hitchcock Medical CenterEnrolling by invitation
-
Swiss Federal Institute of TechnologyUniversity of Zurich; cereneo center for Neurology and RehabilitationRecruitingParkinson Disease | Gait Disorders, NeurologicSwitzerland
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)Recruiting
-
Assuta Hospital SystemsBSP Biological Signal Processing Ltd.Unknown
-
Centre Integre Universitaire de Sante et Services...Not yet recruiting